Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease

Journal of Human Hypertension

Volumn 13, Issue 3, 1999, Pages 203-208

  Singh, R B ^a,b   Niaz, M A ^a   Rastogi, S S ^a   Shukla, P K ^a   Thakur, A S ^a  

^a Medical Hospital and Research Centre Moradabad   (India)

^b MHRC   (India)

Author keywords

Coronary disease; Hypertension; Insulin resistant antioxidant vitamin; Oxidant stress

Indexed keywords

ALKADIENE; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; BETA CAROTENE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID PEROXIDE; MALONALDEHYDE; Q GEL; RETINOL; TRIACYLGLYCEROL; UBIDECARENONE; UNCLASSIFIED DRUG; VITAMIN B COMPLEX;

ADULT; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN RESPONSE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL;

EID: 0033058514     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000778     Document Type: Article

References (37)

1. Enster L, Dallner G. Biochemical, physicological and medical aspects of ubiquinone function. Biochemica Biophys Acta 1995; 1271: 195-204.
2. Langsjoen P, Langsjoen P, Willis R, Folkers R. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med 1994; 15 (Suppl): 265-272.
3. Kontush A et al Plasma ubiquinol is decreased in patients with hyperlipidemia. Atherosclerosis 1997; 129: 119-126.
4. Yokoyama H et al Coenzyme Q10 protects coronary endothelial function from ischemia reperfusion injury via an antioxidant effect. Surgery 1996; 120: 189-196.
5. Iwamoto Y, Yamagami T, Folkers K, Bloomquist CG. Deficiency of coenzyme Q10 in hypertensive rats and reduction of deficiency by treatment with coenzyme Q10. Biochem Biophys Res Comm 1974; 58: 743-748.
6. Yamagami T, Iwanoto Y, Folkers K, Bloomqvist CG. Reduction by coenzyme Q10 of hypertension induced by deoxycorticosterone and saline in rats. Int J Vit Nutr Res 1974; 44: 487-496.
7. Okamoto H, Kawaguchi H, Togashi H. Effect of coenzyme Q10 on structural alterations in the renal membrane of stroke-prone spontaneously hypertensive rats. Biochem Metab Biol 1991; 45: 216-226.
8. Digiesi V, Cantini F, Brodbeck B. Effect of coenzyme Q10 on essential arterial hypertension. Curr Ther Res 1990; 47: 841-845.
9. Digiesi V et al Coenzyme Q10 in essential hypertension. Mol Aspects Med 1994; 15 (Suppl): 275-283.
10. Digiesi V et al Mechanism of action of coenzyme Q10 in essential hypertension. Curr Ther Res 1992; 51: 668-672.
11. Sagar S et al Oxygen free radicals in essential hypertension. Mol Cell Biochem 1992; 110: 103-108.
12. Vijaya Kumar K, Das UN. Are free radicals involved in pathobiology of human essential hypertension. Free Red Res Comm 1993; 19: 59-66.
13. Singh RB et al Plasma levels of antioxidant vitamins and oxidative stress in health and disease. A hospital based case control study. J Nutr Environ Med 1995; 5: 235-242.
14. Ceriello A, Giugliano D, Quantraro A. Antioxidant show an anti-hypertensive effect in diabetic and hypertensive subjects. Clin Sci 1991; 81: 739-749.
15. Stocker R, Bowry WV, Frei B. Ubiquinol-10 protects human low density lipoproteins more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl Acad Sci, USA 1991; 88: 1646-1650.
16. Caballero B. Vitamin E improves the action of insulin. Nutr Review 1993; 51: 339-340.
17. Ursini F, Gambini C, Paciaroni E, Littaru GP. Coenzyme Q10 treatment of heart failure in the Elderly: preliminary results. In: Folkers K, Littaurru GP, Yamagami T (eds). Biomedical and clinical aspects of coenzyme Q10. Vol 6. Elsevier Amsterdam, 1991; pp 473-480.
18. Singh RB et al Randomised, double blind, placebo controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drug Ther 1998; 12: 347-353.
19. Rose GA, Blackburn H, Gilburn RF, Prineas RJ. Cardiovascular Survey Methods World Health Organisation: Geneva, 1982.
20. Chopra RK, Goldman R, Sinatra ST, Bhagvan HN. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Nutr Vit Res 1998; 68: 109-113.
21. Niato C, Kawamura M, Yamamoto Y. Lipid peroxides as the initiating factor of atherosolerosis. Ann NY Acad Sci 1993; 676: 27-45.
22. Lunec J, Hallovan SP, White AG, Dormandy TL. Free radical oxidation (peroxidation) products in serum and synovial fluids in rheumatoid arthritis. J Rheumatol 1981; 8: 233-245.
23. Esterbauer H, Cheeseman KH. Determination of aldehyde peroxidation in products malondialdehyde and 4 hydroxynonenal. Method Enzymol 1990; 186: 407-421.
24. Brubacker G, Vuillemier JP. Vitamin C. In: Curtis HC, Roth M (eds). Clinical Biochemistry, Principles and Methods. Vol 2. Berlin de Gruyter, 1974, pp 989-997.
25. Vuilleumier JP, Keller HE, Gysel D, Hunziker F. Clinical chemical methods for the routine assessment of the Vitamin status in human population. Part 1. The fat soluble vitamins A, E and beta-carotene. Int J Nutr Vit Res 1983; 58: 265-272.
26. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960; 39: 1157-1175.
27. Krentz AJ. Insulin resistance. BMJ 1996; 313: 1385-1389.
28. Singh RB et al Plasma levels of antioxidant vitamins and oxidative stress in patients with acute myocardial infarction. Acta Cardiol 1994; 49: 441-452.
29. Machtey I, Syrkis I, Fried M. Studies of blood ascorbic acid levels in acute myocardial infarction. Clin Chim Acta 1975; 62: 149-151.
30. 6 levels in myocardial infarction. S Afr Med J 1987; 71: 561-563.
31. Ramirej J, Flowers NC. Leucocyte ascorbic acid and its relationship to coronary artery disease in man. Am J Clin Nutr 1980; 33: 2077-2087.
32. Loven DP, Oberley LW. Free radicals, insulin action and diabetes. In: Oberley LW (ed). Superoxidedismutas Vol III. CRC Press: Ecca Raton Florida, 1985.
33. Ferrannini E, Halfner SM, Mitchell BD, Stern MP. Hyperinsulinemia the key features of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-422.
34. Singh RB et al Blood pressure trends, plasma insulin levels and risk factors in rural urban elderly populations of north India. Coronary Art Dis 1997; 8: 463-468.
35. Serbruany VL et al Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CDSI/CD61) receptor expression. J Cardiovasc Pharmacol 1997; 29: 16-22.
36. Auwerx J, Staels B. Leptin: review article. Lancet 1998; 351: 737-742.
37. Yamagami T et al Effect of coenzyme Q10 on essential hypertension, a double blind, controlled study. In: Folkers K, Littarru GP, Yamamura Y (eds). Biomedical and clinical aspects of coenzyme Q. Vol 5. Elsevier: Amsterdam, 1986; pp 337-343.